tiprankstipranks
Trending News
More News >
Trevi Therapeutics Inc (TRVI)
NASDAQ:TRVI
US Market
Advertisement

Trevi Therapeutics (TRVI) Stock Statistics & Valuation Metrics

Compare
526 Followers

Total Valuation

Trevi Therapeutics has a market cap or net worth of $903.58M. The enterprise value is $510.02M.
Market Cap$903.58M
Enterprise Value$510.02M

Share Statistics

Trevi Therapeutics has 121,776,855 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding121,776,855
Owned by Insiders11.78%
Owned by Institutions61.20%

Financial Efficiency

Trevi Therapeutics’s return on equity (ROE) is -0.48 and return on invested capital (ROIC) is -51.00%.
Return on Equity (ROE)-0.48
Return on Assets (ROA)-0.43
Return on Invested Capital (ROIC)-51.00%
Return on Capital Employed (ROCE)-0.51
Revenue Per Employee0.00
Profits Per Employee-1.55M
Employee Count31
Asset Turnover0.00
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of Trevi Therapeutics is ―. Trevi Therapeutics’s PEG ratio is ―.
PE Ratio
PS Ratio
PB Ratio
Price to Fair Value4.18
Price to FCF
Price to Operating Cash Flow-23.21
PEG Ratio

Income Statement

In the last 12 months, Trevi Therapeutics had revenue of 0.00 and earned -47.91M in profits. Earnings per share was -0.47.
Revenue0.00
Gross Profit-147.00K
Operating Income-51.52M
Pretax Income-47.94M
Net Income-47.91M
EBITDA-47.79M
Earnings Per Share (EPS)-0.47

Cash Flow

In the last 12 months, operating cash flow was -42.68M and capital expenditures 13.47M, giving a free cash flow of -42.69M billion.
Operating Cash Flow-42.68M
Free Cash Flow-42.69M
Free Cash Flow per Share-0.35

Dividends & Yields

Trevi Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta0.14
52-Week Price Change174.91%
50-Day Moving Average6.88
200-Day Moving Average5.42
Relative Strength Index (RSI)65.98
Average Volume (3m)1.67M

Important Dates

Trevi Therapeutics upcoming earnings date is Nov 5, 2025, After Close (Confirmed).
Last Earnings DateAug 7, 2025
Next Earnings DateNov 5, 2025
Ex-Dividend Date

Financial Position

Trevi Therapeutics as a current ratio of 10.41, with Debt / Equity ratio of 0.45%
Current Ratio10.41
Quick Ratio10.41
Debt to Market Cap<0.01
Net Debt to EBITDA0.69
Interest Coverage Ratio-12.88K

Taxes

In the past 12 months, Trevi Therapeutics has paid -30.00K in taxes.
Income Tax-30.00K
Effective Tax Rate<0.01

Enterprise Valuation

Trevi Therapeutics EV to EBITDA ratio is -8.02, with an EV/FCF ratio of -10.01.
EV to Sales0.00
EV to EBITDA-8.02
EV to Free Cash Flow-10.01
EV to Operating Cash Flow-10.02

Balance Sheet

Trevi Therapeutics has $203.88M in cash and marketable securities with $891.00K in debt, giving a net cash position of -$202.99M billion.
Cash & Marketable Securities$203.88M
Total Debt$891.00K
Net Cash-$202.99M
Net Cash Per Share-$1.67
Tangible Book Value Per Share$0.99

Margins

Gross margin is -26.03%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-26.03%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%

Analyst Forecast

The average price target for Trevi Therapeutics is $20.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$20.50
Price Target Upside156.25% Upside
Analyst ConsensusStrong Buy
Analyst Count10
Revenue Growth Forecast
EPS Growth Forecast-8.46%

Scores

Smart Score7
AI Score55
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis